Immunome, Inc. (IMNM) Bundle
Immunome Announces 400 Million USD Offering and 40 USD Price Target
Immunome, Inc. (NASDAQ:IMNM) initiated an underwritten public offering of its common stock to raise 400 million USD on December 15, 2025. The biotechnology company intends to utilize the proceeds to advance its pipeline of innovative cancer therapies.
Leerink Partners established a price target of 40 USD for the shares, representing a potential increase of 76.6% from the previous price of 22.65 USD. This optimistic outlook coincides with the company's strategic capital raise.
- Daily high price: 25.30 USD
- Daily trading volume: 12.54 million shares
- Market capitalization: 2.08 billion USD
- 52-week price range: 5.15 USD to 25.30 USD
The stock price increased 13.9% during the trading session, reaching a yearly high. The offering remains subject to market conditions and includes a 30-day option for underwriters to purchase additional shares.
Further details on the company's background and strategy are available at IMNM-history-mission-ownership and IMNM-mission-vision. Investors may also review IMNM-financial-health and IMNM-investor-profile for additional context.
Immunome, Inc. (IMNM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.